Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Treatment Outcomes in Patients with R/R CNSL in the Era of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy

Fan Yang, Rui Liu, Zhonghua Fu, Yuelu Guo, Lixia Ma, Hui SHI, Biping Deng, Xiaoyan Ke, Kai Hu

Blood (2024) 144 (Supplement 1): 3079.

https://doi.org/10.1182/blood-2024-202286

Published: 2024

Journal Articles

Huaier Inhibits the Stemness and Drug Resistance Via Regulating WNT/β-Catenin and YAP Signaling Pathways in IKZF1 del -Ph+ALL

Ziyi Huang, Fen Zhou, Mengxuan Shang, Juan Han, Ping Qu, Hui Shi, Yiren Cheng

Blood (2024) 144 (Supplement 1): 5890.

https://doi.org/10.1182/blood-2024-209814

Published: 2024

Journal Articles

A Compilation of Experiences in Utilizing CAR-T Cell Therapy for Richter's Transformation

Shaomei Feng, Teng Xu, Haidi Liu, Peihao Zheng, Lixia Ma, Hui SHI, Tong Wu, Fan Yang, Kai HU, Xiaoyan Ke

Blood (2023) 142 (Supplement 1): 4638.

https://doi.org/10.1182/blood-2023-182797

Published: 2023

Journal Articles

Assessment of Activities of Daily Living (ADL)Scale Can be Used to Predict Overall Survival after CAR-T Cell Therapy in Elderly Patient(over 70 years of age) with Refractory/Relapsed B-Cell Lymphoma

Fan Yang, Rui Liu, Teng Xu, Zhonghua Fu, Peihao Zheng, Shaomei Feng, Yuelu Guo, Hui SHI, Lixia Ma, Guoai Su, Biping Deng, Xiaoyan Ke, Kai HU

Blood (2023) 142 (Supplement 1): 6922.

https://doi.org/10.1182/blood-2023-177836

Published: 2023

Journal Articles

The Mini-Teddi-R Treatment Demonstrated a High Rate of Remission in Patients with DLBCL Involving the CNS Who Had Previously Been Exposed to BTK Inhibitors

Hui SHI, Kai HU, Xiaoyan Ke

Blood (2023) 142 (Supplement 1): 4507.

https://doi.org/10.1182/blood-2023-184452

Published: 2023

Journal Articles

Exploring the Efficiency and Survival of CAR T-Cell Therapy in DLBCL Patients with MYC and/or TP53 Abnormalities

Peihao Zheng, Rui Liu, Teng Xu, Fan Yang, Shaomei Feng, Yuelu Guo, Lixia Ma, Hui Shi, Hongwei Yu, Biping Deng, Xiaoyan Ke, Kai Hu

Blood (2022) 140 (Supplement 1): 7548–7549.

https://doi.org/10.1182/blood-2022-168018

Published: 2022

Journal Articles

Interpreting Immune Reconstitution and Clinical Outcome By Single-Cell Transcriptomic Analysis in T-ALL Patients Undergoing Donor-Derived CD7 CAR-T Immunotherapy

Hui Shi, Kai Hu, Fan Yang, Zhuojun Liu, Jia Liu, Wei Chen, Jian Yu

Blood (2022) 140 (Supplement 1): 10422–10423.

https://doi.org/10.1182/blood-2022-165035

Published: 2022

Journal Articles

Subsequent Secondary CAR-T Cell Therapy Was Superior to Chemotherapy in Patients with Refractory/Relapsed B-Cell Lymphoma after Failure of Anti-CD19 CAR-T Cell Therapy

Fan Yang, Rui Liu, Teng Xu, Peihao Zheng, Shaomei Feng, Yuelu Guo, Lixia Ma, Hui SHI, Biping Deng, Xiaoyan Ke, Tong Wu, Kai Hu

Blood (2022) 140 (Supplement 1): 10384–10385.

https://doi.org/10.1182/blood-2022-164446

Published: 2022

Journal Articles

Daratumumab-Primed Venetoclax Combined with Cage for Refractory/Relapsed T-Lymphoblastic Leukemia/Lymphoma Patients: Single-Arm, Open-Label, Phase I Study

Hui Shi, Kai Hu

Blood (2022) 140 (Supplement 1): 9480–9481.

https://doi.org/10.1182/blood-2022-165210

Published: 2022

Journal Articles

Secondary Humanized CAR T Cells Salvage Therapy Improves Survival of R/R DLBCL Patients Failed to Murine CD19-CAR T Cells Therapy

Hui SHI, Kai Hu, Xiaoyan Ke, Tong Wu

Blood (2021) 138 (Supplement 1): 4836.

https://doi.org/10.1182/blood-2021-150108

Published: 2021

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation with Conditioning Including Donor Humanized CAR-T Cells for Refractory/Relapsed B-Cell Non-Hodgkin Lymphoma and Multiple Myeloma

Fan Yang, Hui Shi, Yang Lei, Ruiting Li, Teng Xu, Biping Deng, Tong Wu, Xiaoyan Ke, Kai Hu

Blood (2021) 138 (Supplement 1): 557.

https://doi.org/10.1182/blood-2021-146767

Published: 2021

Journal Articles

Auto Hematopoietic Stem Cell Transplantation Combined with Another Target Humanized CAR-T Cells for Refractory/Relapsed B-Cell Non-Hodgkin Lymphoma after Failure of Murinized CD19-CAR-T Therapy

Kai Hu, Fan Yang, Rui Liu, Teng Xu, Peihao Zheng, Shaomei Feng, Yuelu Guo, Hui Shi, Biping Deng, Xiaoyan Ke, Tong Wu

Blood (2021) 138 (Supplement 1): 657.

https://doi.org/10.1182/blood-2021-146801

Published: 2021

Journal Articles

Transcriptomic landscape of circulating mononuclear phagocytes in Langerhans cell histiocytosis at the single-cell level

Blood (2021) 138 (14): 1237–1248.

https://doi.org/10.1182/blood.2020009064

Published: 2021

Includes: Supplemental data

Journal Articles

ASXL2 Is Required for Normal Hematopoiesis and Loss of a sxl2 Leads to Myeloid Malignancies in Mice

Jianping Li, Fuhong He, PhD, Peng Zhang, PhD, Shi Chen, MD PhD, Hui Shi, Yanling Sun, Guo Ying, Hui Yang, Stephen D. Nimer, MD, Qian-Fei Wang, Mingjiang Xu, MD PhD, Feng-Chun Yang, MD PhD

Blood (2016) 128 (22): 1509.

https://doi.org/10.1182/blood.V128.22.1509.1509

Published: 2016

Journal Articles

Upregulation of Mir-99a Is Associated with Poor Prognosis of Acute Myeloid Leukemia and Promotes Myeloid Leukemia Cell Expansion

Xiaohui Si, Xiaoyun Zhang, Xing Hao, Yunan Li, Zizhen Chen, Hui Shi, Feng-Chun Yang, MD PhD, Yuan Zhou, PhD

Blood (2016) 128 (22): 5086.

https://doi.org/10.1182/blood.V128.22.5086.5086

Published: 2016

Journal Articles

Survival and Prognosis of Chinese Patients with Post-Polycythemia Vera Myelofibrosis

Jie Bai, MD PhD, Yuan Zhou, PhD, Lei Zhang, MD, Mengyao Sheng, Rong Li, Hui Shi, Yanping Xue, MD, Mingjiang Xu, MD PhD, Feng-Chun Yang, MD PhD

Blood (2015) 126 (23): 1607.

https://doi.org/10.1182/blood.V126.23.1607.1607

Published: 2015

Journal Articles

Impact of Chemotherapy Delay on Overall Survival for AML with I DH1/2 Mutations: A Study in Adult Chinese Patients

Blood (2015) 126 (23): 4905.

https://doi.org/10.1182/blood.V126.23.4905.4905

Published: 2015

Journal Articles

Combined Loss of Tet1 and Tet2 Promotes B-Cell, but Not Myeloid Malignancies in Mice

Zhigang Zhao, MDPhD, Lin Li, PhD, Meelad Dawlaty, PhD, Feng Pan, PhD, Zhe Li, PhD, Yuan Zhou, PhD, Hui Shi, MD PhD, Shi Chen, MD PhD, Ophelia Weeks, PhD, Weiping Yuan, PhD, Hongyu Ni, PhD, Feng-Chun Yang, MD PhD, Rudolph Jaenisch, PhD, Peng Jin, MDPhD, Mingjiang Xu, MDPhD

Blood (2015) 126 (23): 3650.

https://doi.org/10.1182/blood.V126.23.3650.3650

Published: 2015

Journal Articles

Cell Autonomous Defects of Mesenchymal Stem Progenitor Cells of Patients with CMML Contribute to Impaired Hematopoietic Supportive Activity

Hui Shi, MD PhD, Rong Li, Wen Xing, MD, Jie Bai, MD PhD, Xiaohui Si, PhD, Mingjiang Xu, MD PhD, Yuan Zhou, PhD, Feng-Chun Yang, MD PhD

Blood (2015) 126 (23): 3599.

https://doi.org/10.1182/blood.V126.23.3599.3599

Published: 2015

Journal Articles

ASXL1 Is a Key Regulator for Erythroid Development and Asxl1 Loss Impairs Erythropoiesis In Vivo

Shohei Yamamoto, MD PhD, Hui Shi, MD PhD, Shi Chen, MD PhD, Peng Zhang, PhD, Yuan Zhou, PhD, Mingjiang Xu, MD PhD, Feng-Chun Yang, MD PhD

Blood (2015) 126 (23): 3644.

https://doi.org/10.1182/blood.V126.23.3644.3644

Published: 2015

NARROW

Treatment Outcomes in Patients with R/R CNSL in the Era of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy

Huaier Inhibits the Stemness and Drug Resistance Via Regulating WNT/β-Catenin and YAP Signaling Pathways in IKZF1 del -Ph+ALL

A Compilation of Experiences in Utilizing CAR-T Cell Therapy for Richter's Transformation

Assessment of Activities of Daily Living (ADL)Scale Can be Used to Predict Overall Survival after CAR-T Cell Therapy in Elderly Patient(over 70 years of age) with Refractory/Relapsed B-Cell Lymphoma

The Mini-Teddi-R Treatment Demonstrated a High Rate of Remission in Patients with DLBCL Involving the CNS Who Had Previously Been Exposed to BTK Inhibitors

Exploring the Efficiency and Survival of CAR T-Cell Therapy in DLBCL Patients with MYC and/or TP53 Abnormalities

Interpreting Immune Reconstitution and Clinical Outcome By Single-Cell Transcriptomic Analysis in T-ALL Patients Undergoing Donor-Derived CD7 CAR-T Immunotherapy

Subsequent Secondary CAR-T Cell Therapy Was Superior to Chemotherapy in Patients with Refractory/Relapsed B-Cell Lymphoma after Failure of Anti-CD19 CAR-T Cell Therapy

Daratumumab-Primed Venetoclax Combined with Cage for Refractory/Relapsed T-Lymphoblastic Leukemia/Lymphoma Patients: Single-Arm, Open-Label, Phase I Study

Secondary Humanized CAR T Cells Salvage Therapy Improves Survival of R/R DLBCL Patients Failed to Murine CD19-CAR T Cells Therapy

Allogeneic Hematopoietic Stem Cell Transplantation with Conditioning Including Donor Humanized CAR-T Cells for Refractory/Relapsed B-Cell Non-Hodgkin Lymphoma and Multiple Myeloma

Auto Hematopoietic Stem Cell Transplantation Combined with Another Target Humanized CAR-T Cells for Refractory/Relapsed B-Cell Non-Hodgkin Lymphoma after Failure of Murinized CD19-CAR-T Therapy

Transcriptomic landscape of circulating mononuclear phagocytes in Langerhans cell histiocytosis at the single-cell level

ASXL2 Is Required for Normal Hematopoiesis and Loss of a sxl2 Leads to Myeloid Malignancies in Mice

Upregulation of Mir-99a Is Associated with Poor Prognosis of Acute Myeloid Leukemia and Promotes Myeloid Leukemia Cell Expansion

Survival and Prognosis of Chinese Patients with Post-Polycythemia Vera Myelofibrosis

Impact of Chemotherapy Delay on Overall Survival for AML with I DH1/2 Mutations: A Study in Adult Chinese Patients

Combined Loss of Tet1 and Tet2 Promotes B-Cell, but Not Myeloid Malignancies in Mice

Cell Autonomous Defects of Mesenchymal Stem Progenitor Cells of Patients with CMML Contribute to Impaired Hematopoietic Supportive Activity

ASXL1 Is a Key Regulator for Erythroid Development and Asxl1 Loss Impairs Erythropoiesis In Vivo

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only